• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
WANG Jinan, SHI Wei, SONG Wei, ZHANG Yaqi, ZHANG Yinsheng, XU Hongjiang. Advances in the application of duck hepatitis B animal model in pharmaceutical field[J]. Journal of China Pharmaceutical University, 2018, 49(6): 746-750. DOI: 10.11665/j.issn.1000-5048.20180617
Citation: WANG Jinan, SHI Wei, SONG Wei, ZHANG Yaqi, ZHANG Yinsheng, XU Hongjiang. Advances in the application of duck hepatitis B animal model in pharmaceutical field[J]. Journal of China Pharmaceutical University, 2018, 49(6): 746-750. DOI: 10.11665/j.issn.1000-5048.20180617
shu

Advances in the application of duck hepatitis B animal model in pharmaceutical field

More Information
    Graphical Abstract
    • Abstract
  • The genome, replication mode and nosogenesis of duck hepatitis B virus are similar to those of human hepatitis B virus. In addition, the natural host of duck hepatitis B virus is readily available, cheap and has a high success rate of infection. Therefore, duck hepatitis B virus-infected models have been widely used for drug screening, pharmacological and pathological studies. For drug screening, the model is easy to obtain with high infection success rate and good stability. In the pharmacological research, the model can maintain high levels of viral DNA replication in the hepatocytes and exhibit significant damaged liver phenotypes which can reflect the pharmacological effects of drugs with different mechanisms. Also in the pathologic mechanisms research, the model has entire virus life cycle and maintains a pool of covalent closed-loop DNA in the hepatocytes, which can help scientific researchers better understand human hepatitis B virus. This article reviews the applications of duck hepatitis B animal model in drug screening, pharmacological and pathological studies, also outlooks the application prospect of this model.
    • FullText(HTML)
    • References (22)
  • [1]
    Dandri M,Lütgehetmann M,Petersen J.Experimental models and therapeutic approaches for HBV[C].//Semin Immunopathol,Springer-Verlag,2013,35(1):7-21.
    [2]
    Thomas E,Liang TJ.Experimental models of hepatitis B and C-new insights and progress[J].Nat Rev Gastroenterol Hepatol,2016,13(6):362-374.
    [3]
    Guo WN,Bin Zhu L A,Yang DL,et al.Animal models for the study of hepatitis B virus infection[J].Zool Res,2018,39(1):25-31.
    [4]
    Tang H,Griffin J,Innaimo S,et al.The discovery and development of a potent antiviral drug,entecavir,for the treatment of chronic hepatitis B[J].J Clin Transl Hepatol,2013,1(1):51-58.
    [5]
    Genovesi EV,Lamb L,Medina I,et al.Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection[J].Antimicrob Agents Chemother,1998,42(12):3209-3217.
    [6]
    Marion PL, Salazar FH, Winters MA, et al. Potent efficacy of entecavir(BMS-200475)in a duck model of hepatitis B virus replication[J].Antimicrob Agents Chemother,2002,46(1):82-88.
    [7]
    Foster WK,Miller DS,Marion PL,et al.Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection[J].Antimicrob Agents Chemother,2003,47(8):2624-2635.
    [8]
    Tian X,Li Z,Liu M.Inhibitory effect of BP0018 on hepatitis B virus in vivo[J] Chin J New Drug(中国新药杂志),2016,25(11):1293-1297.
    [9]
    Quinet J, Jamard C, Vaillant A, et al. Achievement of surface antigen clearance in the liver by combination therapy with REP 2139-Ca and nucleoside analogues against chronic hepatitis B[C]//International Liver Congress.2016:12-17.
    [10]
    Le Guerhier F,Thermet A,Guerret S,et al.Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model[J].J Hepatol,2003,38(3):328-334.
    [11]
    Brikh C,Jamard C,Quinet J,et al.Therapeutic effect against hepatitis B of various nucleic acid polymers in the chronic DHBV infection model[J].J Hepatol,2015,62:S518-S518.
    [12]
    Quinet J,Jamard C,Burtin M,et al.Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks[J].Hepatology,2018,67(6):2127-2140.
    [13]
    Cai D,Mills C,Yu W,et al.Identification of the disubstituted?敳瑵?慦汯??業???洠浣畯湭潰杯敵湮楤捳椠瑡祳?慳湰摥?灩牦潩瑣攠捩瑮楨癩敢?整景晲楳挠慯捦礠?潥晰????噩??乂??癩慲捵捳椠湣敯獶?敬硥灮牴敬獹猠楣湬杯?敥湤瘠散汩潲灣敵?慡湲搠?捎慁瀠獦楯摲?晡畴獩楯潮湛?灝爮漼瑩放楁湮獴?業湩?摲畯换欠獁?摥敮汴楳瘠敃牨敥摭?扴票?慲琼琯敩渾甬愲琰攱搲??楢?匵愶氼洯潢渾攨氱永愩?琴礲瀷样椭洴甲爸椸甮洼??椯?孛?崴??椠????湡瑧敮条爠??本牌楩捵??椬????????戾?????戼?????????????benzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids[J].J Virol,2013,87(12):6931-6932.
    [14]
    Liu Y,Peng Y,Lu J,et al.Design,synthesis,and biological evaluation of new 1,2,3-triazolo-2′-deoxy-2′-fluoro-4′-azido nucleoside derivatives as potent anti-HBV agents[J].Eur J Med Chem,2018,143:137-149.
    [15]
    Tohidi-Esfahani R,Vickery K,Cossart Y.The early host innate immune response to duck hepatitis B virus infection[J].J Gen Virol,2010,91(2):509-520.
    [16]
    Hao YH,Li AY,Ding HH,et al.Experimental study on duck hepatitis B virus infection model by different kinds of ducklings and anti-viral effect[J].Chin J Comp Med(中国比较医学杂志),2012,22(11):23-26.
    [17]
    Reaiche GY,Le Mire MF,Mason WS,et al.The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis[J].Virology,2010,406(2):286-292.
    [18]
    Saade F,Buronfosse T,Guerret S,et al.In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes[J].J Viral Hepatitis,2013,20(4):e56-e65.
    [19]
    Koumbi L, Karayiannis P. The epigenetic control of hepatitis B virus modulates the outcome of infection[J].Front Microbiol,2016,6:1491.
    [20]
    Liu F,Campagna M,Qi Y,et al.Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes[J].PLoS Pathog,2013,9(9):e1003613.
    [21]
    Zheng Q,Bai L,Zheng S,et al.Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system[J].Mol Med Rep,2017,16(5):7199-7204.
    [22]
    Liu S,Jia R,Li Q,
    • Related Articles

  • Related Articles

    [1]TU Penghuang, YAO Zhiren, JIN Meiling, NING Guanyu, HUANG Yaping, PAN Ke, YIN Zhiqi. Study of glycosides from Piper sintenense Hatusima[J]. Journal of China Pharmaceutical University, 2024, 55(2): 202-208. DOI: 10.11665/j.issn.1000-5048.2023122704
    [2]CAI Caihong, ZHENG Hao, GAI Cuijuan, DAI Haofu, MEI Wenli, CHEN Huiqin. Secondary metabolites of the endophytic fungus Aspergillus sp.Dq-25 from barnacle[J]. Journal of China Pharmaceutical University, 2023, 54(1): 62-67. DOI: 10.11665/j.issn.1000-5048.20220531001
    [3]FANG Siyang, ZHANG Xinggui, YE Yu, WANG Keqing, YAO Zhiren, HUANG Yaping, ZHANG Jian, QIN Yanhua, YIN Zhiqi. A new ester glycoside compound from Cyclocarya paliurus[J]. Journal of China Pharmaceutical University, 2023, 54(1): 56-61. DOI: 10.11665/j.issn.1000-5048.20221209002
    [4]XIE Jing, FAN Chunlin, XU Jie, ZHANG Jian, YE Wencai, ZHANG Xiaoqi. Alkaloids of Ervatamia pandacaqui[J]. Journal of China Pharmaceutical University, 2021, 52(3): 287-292. DOI: 10.11665/j.issn.1000-5048.20210304
    [5]ZHANG Yilun, ZHAO Xinyi, DONG Shubo, DONG Chao, SHEN Wenbin, DONG Haijuan. Isolation and identification of unknown impurities of alogliptin benzoate[J]. Journal of China Pharmaceutical University, 2020, 51(4): 488-493. DOI: 10.11665/j.issn.1000-5048.20200415
    [6]TAO Junjie, YANG Jie, WEN Xiaodong. Studies on the chemical constituents in the aerial parts of Paris polyphylla var. Yunnanensis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 454-460. DOI: 10.11665/j.issn.1000-5048.20200410
    [7]HUANG Qilong, ZHANG Wanjin, LI Yan, CHEN Juan, ZHOU Baoping, ZOU Xiaohan, ZHANG Chunlei, CAO Zhengyu. Alkaloid constituents from Corydalis decumbens[J]. Journal of China Pharmaceutical University, 2017, 48(5): 563-567. DOI: 10.11665/j.issn.1000-5048.20170509
    [8]WANG Jingyi, DONG Yangyang, QI Chulu, ZHANG Jiayao, ZHANG Minjie, WANG Hao. Chemical constituents of the stem bark of Bombax ceiba L.[J]. Journal of China Pharmaceutical University, 2016, 47(5): 570-574. DOI: 10.11665/j.issn.1000-5048.20160511
    [9]YANG Hanbing, YANG Wenqiang, SONG Min, ZHANG Jian, ZHANG Xiaoqi, YE Wencai. Phenolic constituents of Galla Chinensis and their antiviral activities[J]. Journal of China Pharmaceutical University, 2016, 47(5): 566-569. DOI: 10.11665/j.issn.1000-5048.20160510
    [10]Isolation and Identification of Two Taxane DiterpenoidCompounds[J]. Journal of China Pharmaceutical University, 2001, (3): 32-34.

Catalog

    Get Citation
    PDF
    XML
    Article views (573) PDF downloads (1489) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：366183

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return